Insider Transactions in Q4 2023 at Biomarin Pharmaceutical Inc (BMRN)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2023
|
Barbara W. Bodem Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,180
+50.0%
|
-
|
|
Dec 27
2023
|
Mark J Enyedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,180
+50.0%
|
-
|
|
Dec 27
2023
|
Athena Countouriotis Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,180
+50.0%
|
-
|
|
Dec 21
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.3%
|
$930,000
$93.99 P/Share
|
|
Dec 21
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.25%
|
$630,000
$63.1 P/Share
|
|
Dec 13
2023
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
13,764
-19.81%
|
$1,307,580
$95.3 P/Share
|
|
Dec 01
2023
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,370
+0.55%
|
-
|
|
Dec 01
2023
|
Alexander Hardy Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,371
+39.55%
|
-
|
|
Dec 01
2023
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
17,750
+8.37%
|
-
|
|
Dec 01
2023
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,840
+18.54%
|
-
|
|
Oct 31
2023
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
133
+0.33%
|
$9,177
$69.23 P/Share
|
|
Oct 04
2023
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
10
+0.0%
|
$850
$85.57 P/Share
|